Identification of key genes and molecular pathways in type 2 diabetes mellitus and polycystic ovary syndrome via bioinformatics analyses.

OBJECTIVE Type 2 diabetes mellitus (T2DM) and polycystic ovary syndrome (PCOS) are highly prevalent endocrine system diseases. However, studies on the molecular mechanisms of T2DM and PCOS at the transcriptomic level are still few. Thus, we aimed to reveal the potential common genetic and molecular pathways between T2DM and PCOS via bioinformatics analyses. MATERIALS AND METHODS We downloaded the GSE10946 and GSE18732 datasets for T2DM and PCOS, respectively, from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database. These datasets were subjected to integrated differential and weighted gene co-expression network analyses (WGCNA) to screen common genes. Thereafter, functional enrichment and disease gene association analyses were performed, transcription factor (TF)-gene and TF-miRNA-gene regulatory networks were constructed, and finally, the relevant target drugs were identified. RESULTS We identified common genes (BIRC3, DEPTOR, TNNL3, ADRA2A) in T2DM and PCOS. Pathway enrichment analysis depicted that the common genes were enriched in smooth muscle contraction, channel inhibitor activity, apoptosis, and tumor necrosis factor (TNF) signaling pathways. TFs such as SP7, KLF8, HCFC1, IRF1, and MLLT1 played key roles in TF regulatory networks. Orlistat was indicated to be an important gene-targeting drug. CONCLUSIONS This study is the first study to explore four diagnostic biomarkers and gene regulatory networks for T2DM and PCOS. The findings of our study provide novel insights into the diagnosis and treatment of T2DM and PCOS.

[1]  Jingyun Wang,et al.  Discovery of immune-related diagnostic biomarkers and construction of diagnostic model in varies polycystic ovary syndrome , 2022, Archives of Gynecology and Obstetrics.

[2]  J. Olefsky,et al.  Inflammation in obesity, diabetes, and related disorders. , 2022, Immunity.

[3]  Rafael Riudavets Puig,et al.  JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles , 2021, Nucleic Acids Res..

[4]  K. Baek,et al.  Pathogenetic analysis of polycystic ovary syndrome from the perspective of omics. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  Qi Yu,et al.  Downregulating lncRNA NEAT1 induces proliferation and represses apoptosis of ovarian granulosa cells in polycystic ovary syndrome via microRNA-381/IGF1 axis , 2021, Journal of biomedical science.

[6]  Zi-jiang Chen,et al.  Androgen-induced gut dysbiosis disrupts glucolipid metabolism and endocrinal functions in polycystic ovary syndrome , 2021, Microbiome.

[7]  Yan Jin,et al.  Apoptotic vesicles restore liver macrophage homeostasis to counteract type 2 diabetes , 2021, Journal of extracellular vesicles.

[8]  A. Duszewska,et al.  Chronic Low Grade Inflammation in Pathogenesis of PCOS , 2021, International journal of molecular sciences.

[9]  J. Qiao,et al.  The impact of the gut microbiota on the reproductive and metabolic endocrine system , 2021, Gut microbes.

[10]  Lin Cheng,et al.  Gene Expression Profiling of Type 2 Diabetes Mellitus by Bioinformatics Analysis , 2020, Comput. Math. Methods Medicine.

[11]  M. Nieuwdorp,et al.  Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes , 2020, Frontiers in Immunology.

[12]  A. Aversa,et al.  Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions , 2020, Frontiers in Endocrinology.

[13]  R. Ruslami,et al.  Type 2 Diabetes and its Impact on the Immune System , 2020, Current diabetes reviews.

[14]  H. Yi,et al.  Immunophenotypic Profiles in Polycystic Ovary Syndrome , 2020, Mediators of inflammation.

[15]  Kai-Lee Wang,et al.  Disturbed Gastrointestinal Contractility in a Polycystic Ovary Syndrome Rat Model , 2020, Digestive Diseases and Sciences.

[16]  S. Basit,et al.  Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives , 2019, The application of clinical genetics.

[17]  C. Ling,et al.  Epigenetics in Human Obesity and Type 2 Diabetes , 2019, Cell metabolism.

[18]  X. Bi,et al.  Identification of the key pathways and genes related to polycystic ovary syndrome using bioinformatics analysis. , 2019, General physiology and biophysics.

[19]  M. Prentki,et al.  Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift , 2019, Diabetes & vascular disease research.

[20]  Seema Patel Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy , 2018, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  D. Briscoe,et al.  DEPTOR at the Nexus of Cancer, Metabolism, and Immunity. , 2018, Physiological reviews.

[22]  B. Tarlatzis,et al.  Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. , 2017, Metabolism: clinical and experimental.

[23]  L. Ruilope,et al.  Investigational calcium channel blockers for the treatment of hypertension , 2016, Expert opinion on investigational drugs.

[24]  Núria Queralt-Rosinach,et al.  DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants , 2016, Nucleic Acids Res..

[25]  T. Tomita Apoptosis in pancreatic β-islet cells in Type 2 diabetes. , 2016, Bosnian journal of basic medical sciences.

[26]  F. Petraglia,et al.  Genetic, hormonal and metabolic aspects of PCOS: an update , 2016, Reproductive Biology and Endocrinology.

[27]  P. Spritzer,et al.  Effects of orlistat vs. metformin on weight loss‐related clinical variables in women with PCOS: systematic review and meta‐analysis , 2016, International journal of clinical practice.

[28]  G. Pacini,et al.  Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus , 2016, Endocrine reviews.

[29]  H. Kaneto [Pathophysiology of type 2 diabetes mellitus]. , 2015, Nihon rinsho. Japanese journal of clinical medicine.

[30]  Fan Shen,et al.  A Double Heterozygous Mutation of TNNI3 Causes Hypertrophic Cardiomyopathy in a Han Chinese Family , 2015, Cardiology.

[31]  K. Taguchi,et al.  G-protein-coupled receptor kinase 2 and endothelial dysfunction: molecular insights and pathophysiological mechanisms , 2015, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.

[32]  Byung-Cheol Lee,et al.  Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. , 2014, Biochimica et biophysica acta.

[33]  H. Kobori,et al.  Calcium Channel Blocker Enhances Beneficial Effects of an Angiotensin II AT1 Receptor Blocker against Cerebrovascular-Renal Injury in type 2 Diabetic Mice , 2013, PloS one.

[34]  Frédéric Schütz,et al.  HCFC1 is a common component of active human CpG-island promoters and coincides with ZNF143, THAP11, YY1, and GABP transcription factor occupancy , 2013, Genome research.

[35]  E. Diamanti-Kandarakis,et al.  Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome. , 2013, European journal of endocrinology.

[36]  Y. Liu,et al.  Evaluation of the association between the ADRA2A genetic polymorphisms and type 2 diabetes in a Chinese Han population. , 2012, Genetic testing and molecular biomarkers.

[37]  W. Lieberthal,et al.  Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications. , 2012, American journal of physiology. Renal physiology.

[38]  M. Fernandez,et al.  Inflammation and type 2 diabetes. , 2012, Diabetes & metabolism.

[39]  K. Inoki,et al.  AMPK and mTOR in cellular energy homeostasis and drug targets. , 2012, Annual review of pharmacology and toxicology.

[40]  Tom R. Gaunt,et al.  Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: meta-analysis of four prospective studies , 2011, Diabetologia.

[41]  J. Potter,et al.  Cardiac Troponin Mutations and Restrictive Cardiomyopathy , 2010, Journal of biomedicine & biotechnology.

[42]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[43]  V. Chalifa-Caspi,et al.  Gene expression microarray profiles of cumulus cells in lean and overweight-obese polycystic ovary syndrome patients. , 2008, Molecular human reproduction.

[44]  A. Halpern,et al.  Orlistat in the prevention of diabetes in the obese patient , 2008, Vascular health and risk management.

[45]  S. Elmore Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[46]  U. Boggi,et al.  Lipotoxicity in human pancreatic islets and the protective effect of metformin. , 2002, Diabetes.

[47]  A. Grossman,et al.  Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man. , 1994, The Journal of endocrinology.

[48]  Maysson Ibrahim,et al.  Pathways Enrichment Analysis of Gene Expression Data in Type 2 Diabetes. , 2020, Methods in molecular biology.

[49]  L. Igel,et al.  Obesity Pharmacotherapy. , 2018, The Medical clinics of North America.

[50]  D. Vučić,et al.  Intracellular regulation of TNF activity in health and disease. , 2018, Cytokine.

[51]  S. Recabarren,et al.  [Epigenetics of polycystic ovary syndrome]. , 2017, Revista medica de Chile.

[52]  W. Kerner,et al.  Definition, classification and diagnosis of diabetes mellitus. , 2014, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[53]  P. Anagnostis Metabolic syndrome in the Mediterranean region: Current status , 2012, Indian journal of endocrinology and metabolism.

[54]  Karin Kraft,et al.  [Type-2 diabetes]. , 2010, MMW Fortschritte der Medizin.